Mount Sinai Health System has teamed up RenalytixAI to use artificial intelligence (AI) to identify and treat kidney disease. The partnership between the two hospitals is part of a larger effort by both organizations to develop new ways for doctors to better diagnose diseases like diabetes or heart disease with less reliance on human judgment. The project will draw on anonymised data from three million e-health records in Mount Sinai's system, alongside an extra 43,000 records in its BioMe BioBank, which collects DNA and blood serum to identify biomarkers.
Mount Sinai Health System has teamed up RenalytixAI to use artificial intelligence (AI) to identify and treat kidney disease. Mount Sinai signed a multi-year licence and partnership with the start-up to predict which patients have the highest risk of advanced kidney disease and take steps to treat them early on. The project will draw on anonymised data from three million e-health records in Mount Sinai's system, alongside an extra 43,000 records in its BioMe BioBank, which collects DNA and blood serum to identify biomarkers.